GlassScriptPhysician profile
Christopher R Wilson
NPI 1104098185
$6,847.10
in general payments reported to CMS, 2019-2025
18 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $52.59 · 2021: $624 · 2022: $670 · 2023: $1,503 · 2024: $2,654 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,257.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,198.39 | 2019-2025 | Cardiomems, Mitraclip, Amplatzer Amulet |
| Boston Scientific Corporation | $1,648.64 | 2021-2025 | Avvigo Guidance System, General - Balloon Catheters, Watchman Access System |
| Abiomed | $458.71 | 2020-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $452.42 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.94 | 2021-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $332.87 | 2023-2024 | Inpefa |
| Medtronic, INC. | $310.43 | 2021-2025 | Venaseal, Linq II |
| Novartis Pharmaceuticals Corporation | $308.55 | 2023-2025 | |
| Edwards Lifesciences Corporation | $214.72 | 2024-2025 | Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $124.70 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $120.64 | 2025 | |
| Cvrx, INC. | $96.66 | 2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $76.96 | 2023 | |
| Amgen INC. | $52.92 | 2024 | Repatha |
| Fujifilm Healthcare Americas Corporation | $32.27 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $26.85 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.22 | 2024 | Xarelto |
| Astellas Pharma US INC | $19.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.